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Intermittent fasting (IF) protects against the develop-
ment of metabolic diseases and cancer, but whether
it can prevent diabetic microvascular complications is
not known. In db/db mice, we examined the impact of
long-term IFondiabetic retinopathy (DR).Despitenochange
in glycated hemoglobin, db/db mice on the IF regimen
displayed significantly longer survival and a reduction in DR
end points, including acellular capillaries and leukocyte in-
filtration. We hypothesized that IF-mediated changes
in the gut microbiota would produce beneficial metab-
olites and prevent the development of DR. Microbiome
analysis revealed increased levels of Firmicutes and de-
creased Bacteroidetes and Verrucomicrobia. Compared
with db/db mice on ad libitum feeding, changes in the
microbiome of the db/dbmice on IF were associated with
increases in gut mucin, goblet cell number, villi length,
and reductions in plasma peptidoglycan. Consistent with
the known modulatory effects of Firmicutes on bile acid
(BA) metabolism, measurement of BAs demonstrated a
significant increase of tauroursodeoxycholate (TUDCA),
a neuroprotective BA, in db/db on IF but not in db/db on
AL feeding. TGR5, the TUDCA receptor, was found in the
retinal primary ganglion cells. Expression of TGR5 did not
change with IF or diabetes. However, IF reduced retinal
TNF-a mRNA, which is a downstream target of TGR5
activation. Pharmacological activation of TGR5 using
INT-767 prevented DR in a second diabetic mouse model.
These findings support the concept that IF prevents DR
by restructuring the microbiota toward species produc-
ing TUDCA and subsequent retinal protection by TGR5
activation.
Diabetes-related blindness is a personal catastrophe for
the individual and affects more than 4.2 million Americans
(1). Although diabetic retinopathy (DR) is commonly
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classified as a microvascular complication of diabetes, it is
now recognized that changes in the neural cells of the
retina occur early in the natural history of the disease and
that these changes precede alterations in the microvascula-
ture (2,3). Current therapies for DR, such as laser photoco-
agulation, injection of anti-VEGF antibodies, or vitreoretinal
surgery (4), only treat late-stage disease and selectively
target the microvascular component of the disease, whereas
therapies for the early stages are limited to preventive strat-
egies, such as lifestyle changes.
Chronic calorie restriction and intermittent fasting (IF)
represent nonpharmacological strategies for prevention
and treatment of diseases, such as diabetes, obesity, and
aging. However, calorie restriction can lead to nutrient
deficiencies and fatigue (5,6), low metabolic rate, and
increased risk for subsequent obesity (7), infertility (5),
suppression of immunity (8), and susceptibility to viral
infections (9,10). IF prevents the adverse effects of calorie
restriction as it restricts feeding to only a part of the day
or to certain days per week. Thus, IF may be a more ben-
eficial strategy compared with chronic calorie restriction as
it combines the beneficial effects elicited by fasting physiol-
ogy and a recovery period during the feeding phase that
facilitates regeneration and promotes tissue repair (11).
Accumulating evidence indicates that the gut micro-
biota contribute to key physiological functions, such as
energy metabolism, metabolic signaling, and regulation of
integrity of the gut barrier (12–14). Individuals with chronic
diseases such as diabetes exhibit altered bacterial composi-
tion (15), which likely not only influences glucose metab-
olism but also, we reasoned, may contribute to development
of complications. Gut microbes have a symbiotic relation-
ship with the host: they digest exogenous, indigestible foods
generating secondary metabolites that can affect host phys-
iology andmetabolize endogenous substrates in the absence
of food during prolonged fasting.
An example of endogenous metabolites being converted
to beneficial secondary metabolites by the microbiome is
the generation of secondary bile acids (BAs). Primary BAs
generated by the liver are highly hydrophobic and can
cause colitis; however, intestinal bacteria convert them to
more hydrophilic, less toxic, secondary BAs that are potent
agonists for nuclear receptors and have physiological func-
tions. Using the db/db mouse and an IF (fasting every other
day) regimen for 7 months, we showed that IF prevented
development of DR and increased generation of a second-
ary BA and neuroprotective agent tauroursodeoxycholate
(TUDCA). We further demonstrated the relevance of TUDCA
by demonstrating localization of TGR5, the receptor that
mediates TUDCA’s effects in the retina. In addition, the
pharmacological activation of TGR5 using INT-767 in a sec-
ond diabetes model prevented development of DR.
RESEARCH DESIGN AND METHODS
IF Treatment of Diabetic Animals
Male B6.BKS(D)-Leprdb/J (stock number: 000697) homo-
zygous Leprdb/db were diabetic and heterozygous Leprdb/m
mice were used as controls (denoted as db/db and db/m
hereafter). All mice were obtained from The Jackson
Laboratory (Bar Harbor, ME) and housed in the institu-
tional animal care facilities at the University of Florida
(IACUC #201106420) with strict 12 h:12 h light:dark
cycle; all studies were repeated at Indiana University (IACUC
#10604 and #11167). Blood glucose levels were tested
every 2 weeks in db/db mice. Animals were considered
diabetic and used in the IF experiment if the serum glucose
level was above 250 mg/dL on two consecutive measure-
ments. The animals were fed ad libitum (AL) before the IF
was initiated at 4 months of age. The db/m and db/dbmice
were each divided in two subgroups, AL feeding (control)
and IF, wherein the animals were fasted for 24 h every
other day for 7 months, beginning at night (Fig. 1A).
Glycated hemoglobin was measured using the A1CNow+
kit (Bayer HealthCare, Sunnyvale, CA) on the day prior to
euthanasia.
INT-767 Treatment of Diabetic Animals
Eight-week-old male DBA/2J mice (stock number: 00671)
were obtained from The Jackson Laboratory and main-
tained on a 12 h:12 h light:dark cycle. Mice were injected
with streptozotocin (STZ) (Sigma-Aldrich, St. Louis, MO)
intraperitoneally (40 mg/kg made freshly in 50 mmol/L
sodium citrate buffer, pH 4.5 [vehicle]) for 5 consecutive
days or with vehicle only. Blood glucose levels were mea-
sured 1 week after the last STZ injection, and mice with
glucose levels .250 mg/dL on 2 separate days were
considered diabetic. DBA/2J mice were fed with a Western
diet (WD) (21% milk fat, 0.2% cholesterol, TD88137)
obtained from Harlan-Teklad (Madison, WI) after diabetes
onset in the STZ groups and were treated for 8 weeks with
either WD or WD containing INT-767 (30 mg/kg bw/day)
(Intercept Pharmaceuticals, New York, NY) (18).
Acellular Capillaries
The eyes were fixed in 2% formalin, and trypsin digest was
performed for analysis of acellular capillaries as previously
published (16).
Microbiome Analysis
Fecal samples (n = 180) were obtained by collection every
4 h for 48 h. Genomic DNA was isolated from;0.1 g using
the PowerSoil DNA Isolation Kit (MO Bio, Carlsbad,
CA), according to manufacturer’s protocol. DNA was
sent to Second Genome, Inc. (San Francisco, CA) for 16S
rRNA gene V4 sequencing with the MiSeq platform. The full
report and statistical analysis from Second Genome is
available upon request.
Colon Morphometric Analysis
Colon tissue was collected at termination of the experi-
ment, fixed in 10% buffered formalin, and paraffin-
embedded according to standard procedures at the Indiana
University–Purdue University Indianapolis Pathology Core.
Ten-micrometer sections were cut and stained by either
hematoxylin and eosin or periodic acid Schiff for mucin.
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Entire sections were scanned with an Axio Scan Z1 (Zeiss)
and a 203 objective. Morphometric analysis of goblet
cells, villi length, and muscularis thickness was undertaken
using a Lumenera Infinity 1-2C camera and NIS Elements
software (Nikon Instruments, Melville, NY).
Peptidoglycan ELISA
Plasma samples were diluted 1:10 and analyzed for pep-
tidoglycan levels using the mouse peptidoglycan ELISA kit
(MBS263268; Mybioscource Inc., San Diego, CA), accord-
ing to manufacturer’s instructions.
BA Analysis
At the termination of the experiment, whole blood was
collected by cardiac puncture and transferred in EDTA-coated
tubes. Plasma was separated and frozen at 280°C. Samples
were sent to Metabolon Inc. (Morrisville, NC), and global
metabolic analysis was performed with their Metabolon
Platform using a Waters ACQUITY ultra-performance liquid
chromatography and a Thermo Scientific Q-Exactive high
resolution/accurate mass spectrometer interfaced with a heated
electrospray ionization source and Orbitrap mass analyzer
operated at 35,000 mass resolution. The full report and sta-
tistical analysis from Metabolon is available upon request.
Quantitative Real-time PCR
Total RNA was extracted from mouse retinal tissue using
RNeasy Mini kit (Qiagen, Germantown, MD), and reverse
transcription was performed, according previous pub-
lished methods (17). Validated primers for Gpbar1 (TGR5),
Tnf, and endogenous controls B2m and Ppia were pur-
chased from Qiagen, and quantitative real-time PCR was
carried out using SYBR Green (Qiagen).
Immunofluorescence Staining
Enucleated eyes were fixed in 4% paraformaldehyde over-
night at 4°C. The next day, eyes were incubated with 30%
sucrose for 48 h and then quickly frozen in optical cutting
temperature compound. Retinal cross-sections (12 mm)
were cut at 220°C. The following antibodies were used
for immunostaining: rabbit monoclonal to IBA-1 (019–
19741, Wako; 1:500), rat monoclonal to CD45 (clone
Figure 1—IF feeding prolonged survival of db/db mice without improving glycemic control. A: Depiction of the experimental protocol with
the treatment groups. Mice were put on IF diet at 4 months of age and were held on IF for 7 months. ZT represents zeitgeber time, i.e., time
when the lights went on. B: Glycated hemoglobin levels in db/db-AL and db/db-IF mice were higher compared with db/mmice; however, IF did
not correct glycated hemoglobin levels. Data represent means 6 SEM (n = 6–39). *P , 0.05. C: db/db-AL had reduced survival compared
with db/m mice. IF improved survival rate of db/db-IF mice compared with that of normal controls. *P , 0.05.
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30-F11, R&D Systems; 1:50), rabbit polyclonal to GPCR
TGR5 (ab72608, Abcam; 1:250), and monoclonal murine
anti-NeuN (clone A60, MAB377MI, EMD Millipore; 1:250).
Sections were preincubated with 5% goat serum (Invitro-
gen) in PBS for 1 h, followed by incubation with primary
antibodies (in 1% normal goat serum) overnight at 4°C. As
a secondary antibody, Alexa Fluor 488 was used for TGR5
and IBA-1, and Alexa Fluor 594 was used for NeuN and
CD45 (Invitrogen). Positive cells were counted from 3 to
5 sections at 100-mm intervals for each eye, on at least four
images per section at 203 magnification. Retinal sections
were imaged using a confocal scanning laser microscope
(ZEISS LSM 700 confocal microscope system with Axio
Observer; Carl Zeiss Mditec, Jena, Germany), and coloc-
alization was analyzed by using ZEN lite software.
Statistical Analysis
Survival curve was plotted by Kaplan-Meier method, and
the significance of the differences was determined by log-
rank test. The differences in gene expression, metabolites,
and acellular capillaries were analyzed by two-way ANOVA
followed by Tukey honest significant difference post hoc
test (GraphPad Prism, La Jolla, CA). Statistical analysis
methods for microbiome and metabolites are available
upon request.
RESULTS
IF Improved Survival Without Impacting Glycated
Hemoglobin Levels
Four-month-old db/m and db/db mice were fed either an
AL diet or were fasted on an every other 24-h interval (IF)
for 7 months (Fig. 1A). Glycated hemoglobin levels were
not affected by the IF regimen and remained higher in both
db/db cohorts compared with controls (Fig. 1B). However,
despite no change in glycated hemoglobin, the survival rate
increased significantly in db/db mice on the IF regimen
(db/db-IF) compared with db/dbmice on AL feeding (db/db-
AL) (Fig. 1C).
IF Prevented Development of Acellular Capillaries
and Infiltration of Inflammatory Cells in the Retina
of db/db Mice
We next examined the impact of IF on the development
of DR in db/dbmice by enumerating acellular capillaries (Fig.
2A–D) (19). As expected, db/db-AL mice showed increased
numbers of acellular capillaries (Fig. 2C) compared with
age-matched db/m-AL mice (Fig. 2A). However, db/db-IF
mice (Fig. 2D and E) did not demonstrate an increase
in acellular capillaries. As increases in retinal levels of
inflammatory cells are another feature of DR, cryosec-
tions were examined for changes in activated microglia
using IBA-1 staining and differences in infiltrating hema-
topoietic cells using CD45 staining. db/db-AL mice showed
a significant increase in IBA-1+ cells compared with db/m-AL
mice and db/db-IF mice (Fig. 2F). CD45+ cell infiltration
was significantly increased in the db/db-AL mice com-
pared with the db/m-AL mice and db/db-IF mice (Fig. 2G).
Overall, IF protected db/dbmice from developing histological
features of DR.
Long-term IF Altered the Gut Microbiome Composition
The composition and diversity of the microbiome is in-
tegrated with the pathophysiology of diabetes. For exam-
ple, certain bacteria are shown to induce diabetes (20),
whereas others alleviate it (21). Thus, we hypothesized
that the beneficial effects of IF on DR would, at least in
part, be mediated through changes in microbiota compo-
sition. Fecal samples were collected and genomic DNA
sequencing was used to discover and distinguish various
bacterial taxa. A total of 1,363 filtered operational taxo-
nomic units (OTUs) were detected. Sample richness and
Shannon diversity (Supplementary Fig. 1A–F) were not
changed by the implementation of IF but b diversity,
a measure of the between-sample diversity, showed clear
differences between db/db-AL and db/m-AL (Fig. 3A),
db/m-IF vs. db/m-AL (Fig. 3B), and db/db-IF vs. db/db-AL
(Fig. 3C) mice. Principal component analysis of bacteria
also demonstrated a clear separation of the four main
groups (db/m AL, db/db AL, db/m IF, and db/db IF). The AL
groups were closer to each other, whereas the IF groups
diverged more (Fig. 3D). This evidence suggests that IF
restructured a distinct microbiome in diabetic compared
with control mice.
The most represented phyla were Bacteroidetes,
Firmicutes, Verrucomicrobia, Tenericutes, Actinobacteria,
and Proteobacteria. The relative proportions of these
varied dramatically among the experimental groups but
the majority of bacteria belonged to the Bacteroidetes,
Firmicutes, and Verrucomicrobia phyla (Fig. 3E). The ratio
of Firmicutes/Bacteroidetes (F/B) has been widely used as
an indicator of changes in the microbiome with obesity
(22). The F/B ratio was not altered in the db/m-IF mice
(Fig. 3E); however, it was dramatically increased in the
db/db-IF mice due to a significant increase of Firmicutes
and a significant reduction of Bacteroidetes (Fig. 3E). Apart
from changes observed in the F/B ratio, Verrucomicrobia
also changed significantly with IF showing an increase in
db/m-IF and a reduction in db/db-IF mice (Fig. 3E). Overall,
these data indicate that IF resulted in a more dramatic
restructuring of the microbiota composition in diabetic
mice, with a significant expansion of Firmicutes at the
expense of Bacteroidetes and Verrucomicrobia.
To understand how the microbiota composition was
altered at the genus level, the differential taxa in each
group were assessed (Fig. 4A–C). Among the differen-
tial taxa between db/m-AL and db/db-AL cohorts, the
db/db-AL mice were enriched in Lactobacillus, Bifidobacterium,
Bacteroides, and Akkermansia and were deficit in species of
Oscillospira and Ruminococcus (Fig. 4A). The IF regimen in
the db/db mice caused enrichment of species of the genus
Lactobacillus, Oscillospira, and Ruminococcus and reduc-
tion of species of the genus Akkermansia, Bacteroides, and
Bifidobacterium (Fig. 4B and C). Interestingly, the difference
in the microbiota between fed and fasting state in the
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IF cohorts was very small, limited to only 24 bacteria in
db/db-IF mice and 69 bacteria in db/m-IF mice (Supplemen-
tary Fig. 2A and B). Yet, we identified certain common
species that were increased by fasting in both db/m-IF
and db/db-IF cohorts, mostly species in the Lachnospiraceae
and Ruminococcaceae families with representatives from
Oscillospira and Ruminococcus genera. On the other hand,
species of the genus Bifidobacterium were commonly re-
duced by the IF diet. A list of the common and unique
enriched bacterial species is shown in Supplementary Fig.
2C and the common or uniquely reduced bacteria is shown
in Supplementary Fig. 2D.
IF is known to influence diurnal rhythms and selected
microbes in the gut exhibit diurnal changes (23,24). We
investigated which taxa displayed diurnal patterns in
healthy db/m-AL mice and whether these taxa were af-
fected by either the presence of diabetes or IF (25). Sur-
prisingly, we found only 34 OTUs showing diurnal cycling.
Among these were members of Lachnospiraceae and
Ruminococcaceae families, specifically species of Oscillo-
spira and Ruminococcus. Examples of bacteria with diurnal
regulation are shown in Supplementary Fig. 3.
Although there were few taxa differentially regulated
by feeding/fasting or diurnal cycling, the evolutionary
pressure of fasting and refeeding in combination with the
host metabolic response to fasting led to the distinct restruc-
turing of the microbiota in the db/m-IF and db/db-IF
mice. Members of the order Clostridiales (Fig. 4D) and mem-
bers of the Ruminococcaceae (Fig. 4E) and Lachnospiraceae
families (Fig. 4F) were uniquely equipped to adapt, expand,
and survive under IF conditions in db/db but not in
db/m mice. Lactobacillus (Fig. 4G) was enriched in both
db/m-IF and db/db-IFmice, whereas the generaBifidobacterium
(Fig. 4H) and Clostridium (Fig. 4I) were reduced in both
groups. On the other hand, Oscillospira (Fig. 4J), Rumino-
coccus (Fig. 4K), and Turicibacter (Fig. 4L) were enriched
Figure 2—IF reduced DR in db/dbmice.A–D: Representative images of the trypsin-digested retinas from the four experimental groups: db/m
AL (A), db/m IF (B), db/db AL (C), and db/db IF (D). Arrows indicate acellular capillaries. Scale bars: 10 mm. E: Enumeration of acellular
capillaries per mm2 retinal area. Data represent means6 SEM (n = 10). *P, 0.05, one-way ANOVA. F: Enumeration of IBA-1+ cells per mm2
retinal area from immunofluorescence-stained retina cryosections. Data represent means 6 SEM (n = 3). G: Enumeration of CD45+ cells
permm2 retinal area from immunofluorescence-stained retina cryosections. Data representmeans6SEM (n= 3–5). F andG: *P, 0.05, two-way
ANOVA.
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specifically in the db/db-IF mice, whereas Bacteroides (Fig.
4M), Akkermansia (Fig. 4N), and Allobaculum (Fig. 4O) were
reduced only in the db/db-IF mice. We reasoned that these
unique changes in the microflora of the db/db-IF mice could
promote the integrity of the gut barrier.
IF Promoted Restoration of Diabetes-Induced
Gut Pathology
As disruption of the gut barrier integrity is an important
mechanism of disease, we examined whether IF benefi-
cially impacted colon morphology as measured by goblet
cell number and villi length (Fig. 5). db/db-AL mice had
reduced numbers of goblet cells (Fig. 5B and E) and reduced
villi length (Fig. 5G and J). However, IF resulted in pres-
ervation of colon morphology in the db/db-IF mice, as
goblet cell number (Fig. 5D and E) and villi length (Fig. 5I
and J) were similar to nondiabetic mice. No changes with
diabetes or IF were observed in the thickness of the
muscularis (Fig. 5K–O).
Increases in bacterial products in plasma are indicative
of intestinal barrier dysfunction or disruption. We mea-
sured peptidoglycan in plasma samples from our cohorts.
As shown in Fig. 5P, db/db-AL demonstrated a significant
increase in plasma peptidoglycan levels supportive of
increased gut permeability. IF resulted in a decrease in
gut permeability when db/db-IF mice were in the fasted
state as there was a significant reduction of circulating
peptidoglycan levels. However, when the db/db-IF mice
were in the fed state this potentially beneficial change
was lost.
Figure 3—IF resulted in distinct changes in the microbiota of db/db mice. A–C: b Diversity (presence/absence ordination): Dimensional
reduction of the Jaccard distance on presence/absence OTU table, using the PCoA ordination method. A: db/m-AL (green circles) vs.
db/db-AL (blue triangles) mice; samples separated along axis 2 according to sample type. B: db/m-AL (green triangles) vs. db/m-IF (feeding,
red triangles; fasting, red circles) mice; samples separated along axis 2 according to type, which indicated that samples from IF and AL
treatments have different incidences of OTUs.C: db/db-AL (blue triangles) vs. db/db-IF (feeding, purple triangles; fasting, purple circles)mice;
samples separated along axis 1 according to type. Samples from db/db-AL mice had a smaller degree of variation in microbiome b diversity
than db/db-IF samples. P = 0.001 in all comparisons; n = 5 mice/group. D: Principal component analysis (PCA) of microbiota. Relative
abundance of bacteria present in at least 10% of the samples (n = 180) was used. Samples grouped by both disease (spheres, db/m; cubes,
db/db) and treatment (blue, AL; red, IF) but less clearly by feeding/fasting within the IF groups. Note that the AL cohorts are closer to each
other, whereas the IF cohorts were much further apart, suggesting bigger differences in the microbiomes of db/m-IF and db/db-IF mice. E:
Relative proportions of the six most abundant phyla (the aggregate relative abundance for each of the phyla not represented here is less than
0.1). aP, 0.01 vs. db/m-AL; bP, 0.001 vs. db/m-AL; cP, 0.05 vs. db/db-AL; dP, 0.001 vs. db/db-AL; eP, 0.05 vs. db/m IF (feeding); fP,
0.001 vs. db/m IF (feeding); gP , 0.05 vs. db/db IF (fasting). All OTUs (detected in at least 10% of the samples) from all samples per each
group were used, irrespective of zeitgeber time. p., phylum.
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Figure 4—IF effects on microbiome composition at the genus level. A: Genera that show statistically significant changes in db/db-AL vs.
db/m-AL mice. B: Genera that were statistically different in db/db-IF vs. db/m-IF mice in the feeding phase. C: Genera that were statistically
different in db/db-IF vs. db/m-IF in the fasting phase. Points are OTUs belonging to each respective genus. Features were considered
significant if false discovery rate–corrected P value #0.05 and the absolute value of log2 fold change $1. D–O: Time course of relative
bacterial abundances of selected taxa during the 48-h cycle of IF regimen are shown. ZT represents zeitgeber time, i.e., time when the lights
went on. Diurnal oscillations in selected taxa and IF effects: o. Clostridiales (D), f. Ruminococcaceae (E), f. Lachnospiraceae (F), g.
Lactobacillus (G), g. Bifidobacterium (H), g. Clostridium (I), g. Oscillospira (J), g. Ruminoccocus (K), g. Turicibacter (L), g. Bacteroides (M), g.
Akkermansia (N), and g. Allobaculum (O). Data are sums of relative abundance of all OTUs within each genus6 SEM. f., family; g., genus; o.,
order.
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IF Altered BA Metabolism
We next tested whether the microbial changes induced by
IF could generate beneficial metabolites. BAs are known to
alter the gut microbiome composition (26), and conversely,
the microbiome is known to alter the BA pool (27). Thus, we
reasoned that the observed microbiome changes induced
by IF would impact BA metabolism in the db/db mice.
Metabolic analysis of plasma from the experimental cohorts
identified the primary BA cholate but not chenodeoxycholate.
A list of BAs found in the plasma is shown in Supplementary
Table 1.
Cholate was increased in the db/db-AL mice compared
with db/m-AL mice and was reduced in the db/db-IF mice
(Fig. 6A). Deoxycholate, the secondary BA that is produced
by the activities of 7a-dehydroxylase, an enzyme found
in intestinal bacteria, was moderately increased with IF
especially during the fasting period (Fig. 6B), supporting
intestinal transformation of BAs. However, the ratio of
conjugated to unconjugated BA was increased in the db/db-IF
compared with db/m-IF mice during feeding, suggesting
that there may be a reduction of bacteria that express bile
salt hydrolase activity required to deconjugate primary
and secondary BAs in the db/db-IF mice. A significant
reduction of Bifidobacterium (Fig. 4H), Clostridium (Fig. 4I),
and Bacteroides (Fig. 4M) was observed, and these bacteria
are known to express bile salt hydrolase, which may be
responsible, in part, for these observed changes in levels
of conjugated to unconjugated secondary BAs.
An increase in BA products indicative of 7a- and 7b-
hydroxysteroid dehydrogenase (HSDH) enzymatic activity
was also found. Taurochenodeoxycholate (TCDCA) was
identified and significantly increased in the db/db-IF mice
(Fig. 6C). TCDCA is converted to TUDCA by the actions of both
7a- and 7b-HSDH (28), and TUDCA was significantly in-
creased in the plasma of db/db-IF mice (Fig. 6D). As taurine-
conjugated secondary BAs are potent activators of TGR5 (29),
we hypothesize that the beneficial effects we observed follow-
ing IF were due to an increase in TUDCA synthesis in the gut.
Figure 5—IF treatment affected gut morphology. A–D: Periodic acid Schiff (PAS) staining showing mucin-positive goblet cells. Diabetes
reduced goblet cell number, but IF prevented this reduction. E: Quantification of goblet-positive cells. Data represent number of goblet
cells/villus. *P , 0.05, n = 13–30 villi/group. F–I: Hematoxylin and eosin (H&E) staining of colon. The length of villi was reduced significantly
with diabetes, but IF restored levels to normal. J: Quantification of the villi length, in pixels. *P, 0.05, n = 17–26 villi/group. K–N: Hematoxylin
and eosin staining of the muscularis layer.O: Quantification of the muscularis width. Twenty measurements distributed evenly were done on
each section, and data represent averages per section in pixels 6 SD; n = 4–7 sections/group. In all cases, one section per mouse was
analyzed. Scale bars: 50 mm. P: Peptidoglycan, a component of bacterial cell wall, was measured in plasma from the cohorts using ELISA.
Data represent means 6 SD (n = 3–5). *P , 0.05, two-way ANOVA.
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TGR5 Activation Reduces Acellular Capillaries
and Inflammation in the Diabetic Retina
To determine whether TUDCA could mediate beneficial
effects in the retina, we examined TGR5 expression. TGR5
was localized primarily to the ganglion cell layer of the retina
(Fig. 7A). Neither diabetes nor the IF regimen changed
the localization or expression of TGR5 protein (Fig. 7B–F),
as assessed by immunohistochemistry, or changed TGR5mRNA
levels (Fig. 7G). However, TNF-a, a downstream target
of TGR5, was reduced significantly by IF in the diabetic
cohort (Fig. 7H). To further support the role of retinal TGR5, we
asked if pharmacological activation of TGR5 would prevent DR.
Previously, we characterized the novel highly potent semisyn-
thetic BA derivative and dual TGR5/FXR agonist INT-767 (18).
INT-767 was tested in a second diabetes model, DBA/2J
mice treated with STZ and placed on a high-fat diet. This
model exhibits a more rapid progression of the vascular and
inflammatory end points associated with DR (30) and di-
abetic nephropathy (31) and replicates the natural history
andmetabolic characteristics of humanmetabolic syndrome
and type 2 diabetes (31,32). INT-767 treatment of diabetic
mice resulted in a marked reduction in the number of
acellular capillaries (Fig. 7I) and reduced numbers of
CD11b+ macrophages (Fig. 7K), CD45+ leukocytes (Fig. 7J),
and activated IBA-1+ microglia within the retina (Fig. 7L).
DISCUSSION
The salient findings of this study suggest that restructur-
ing of the microbiome by IF favors generation of secondary
BAs, such as TUDCA, eliciting protective effects in the
retina (Fig. 8). Development of acellular capillaries, acti-
vation of retinal microglia, and infiltration of peripheral
immune cells into the retina were all reduced by IF in the
db/dbmice. IF produced a reconfiguration of the microbiota
in the db/db mice resulting in an enrichment in Firmicutes
and a reduction in Bacteroidetes. Interestingly, this was not
observed for db/m mice undergoing IF, indicating that the
diabetic microenvironment benefited Firmicutes expansion.
High F/B ratio has been associated with healthy obesity
(33,34) and increased capacity for harvesting energy (22).
In addition, a high F/B ratio has been implicated in regu-
lating fat storage (35) and is consistent with our findings
wherein IF did not change the weight of the db/db mice
but promoted a healthier obese phenotype with increased
longevity.
Another example of a healthy obese phenotype associ-
ated with expansion of Firmicutes is the case of black
bears. During the summer when active and feeding, these
bears experience a healthy weight gain and an expansion of
Firmicutes (36). Our study provides support for the clinical
observation that some obese individuals are metabolically
healthy (ranging from 3 to 57%, depending on the study)
(13) and may have a gut microbiota structure that con-
tributes to this beneficial outcome.
BAs are significant modulators of the gut microbiome
as they exhibit antimicrobial activities and can inhibit
bacteria outgrowth (37). Members of the Firmicutes phy-
lum are expanded in high BA conditions, whereas members
of Bacteroidetes and Actinobacteria (Bifidobacterium) are
reduced (26). This finding is particularly relevant, as it
appears that the db/db-AL mice have increased cholate
compared with db/m-AL mice. The altered BA metabolism
observed in the diabetic mouse effectively drove the
restructuring of the diabetic microbiota toward the unique
composition with high F/B ratio.
The observed changes in the gut microbiome of db/db-IF
mice were deemed advantageous for gut and intestinal
barrier integrity. We used plasma peptidoglycan as a sur-
rogate for gut barrier function. Peptidoglycan levels were
increased in diabetes, and the IF diet reduced the levels
during fasting. This suggests that gut barrier integrity is
compromised by diabetes and that the IF regimen (during
the fasting day) can improve it. Our results are in agree-
ment with a recent study demonstrating that hyperglyce-
mia drives the increased intestinal permeability observed
in diabetes (38). In our model, when diabetic mice are under
IF, glucose remains elevated during the feeding day of the IF
regimen but is reduced during the fasting phase of the IF
regimen. Furthermore, the composition of the leaked bac-
teria may be important in driving the low-grade systemic
inflammation indiabetes (39). Peptidoglycan is a component
of gram-positive bacteria, and endotoxin is mostly derived
from gram-negative bacteria. Firmicutes are gram positive,
and Bacteroides are gram negative (40). Thus, our results
suggest that the reduction of peptidoglycan occurring in
the db/db mouse on the IF regimen signals a transient
Figure 6—IF enhanced BA metabolism with increases in the neuro-
protective BA TUCDA. Analysis of plasma samples for BA metab-
olites cholate (A), deoxycholate (B), TUDCA (C), and TCDCA (D).
TCDCA and TUDCA were significantly increased with IF diet in the
db/db-IFmice. TCDCA is converted to TUDCAby the actions of both
7a- and 7b-HSDH. Values for each sample are normalized by sample
volume/utilized for extraction. Each biochemical is then scaled to set
the median equal to 1. Missing values are imputed with the minimum.
Data represent means 6 SD (n 5 4–6). *P , 0.05, two-way ANOVA.
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Figure 7—TGR5 activation using the BA agonist INT-767 prevented DR. A: TGR5 immunofluorescence staining is located in the retinal
ganglion cell layer of a db/m control mouse. NeuN is used as a marker of ganglion cells. TGR5: green, NeuN: red, and DAPI: blue. INL, inner
nuclear layer; GCL, ganglion cell layer; ONL, outer nuclear layer.B–E: TGR5 andNeuN staining in db/m-AL (B), db/m-IF (C), db/db-AL (D), and
db/db-IF (E). F: Quantification of the fluorescence intensity of TGR5 in the retinal ganglion cell layer. Data represent means6 SD (n5 10–12).
G: TGR5 mRNA expression in retinas from all cohorts. Data represent means6 SD (n5 5–7). H: TNF-amRNA expression in retinas from all
cohorts. Data represent means6 SD (n5 4–5). *P, 0.05, two-way ANOVA. I–L: Effects of INT-767 on retinas of 20-week STZ-diabetic DBA/
2J mice. I: INT-767 protects from development of DR as measured by enumeration of acellular capillaries. J: INT-767 returns CD451 cell
numbers to levels seen in no diabetic mice. K: Inflammatory monocytes are reduced in the INT-767–treated mice, as shown by quantification
of CD11b1 cells. L: INT-767 reduced numbers of IBA-11 cells within the retina. C, DBA/2J mice fed with vehicle; C1INT, DBA/2J mice fed
with INT-767; D, STZ/WD mice; D1INT, STZ/WD with INT-767. Data represent means6 SD (n5 6 per group). *P, 0.05, one-way ANOVA.
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restoration/improvement in gut integrity and could also
lead to a transient reduction in endotoxemia. However, this
remains to be tested.
In diabetes, cholesterol and BA metabolism is altered
(41). Thus, we focused our efforts in understanding how
remodeling of the microbiota by IF affected biotrans-
formation of the BA pool. Primary BAs are synthesized
from cholesterol in the liver and act as detergents for the
emulsification of dietary fats and as endocrine hormones
for the regulation of glucose and lipid metabolism (42,43).
Conjugated or unconjugated primary BAs enter the gall-
bladder and are released in the small intestine, where BA
are structurally modified into various secondary BAs that
are less toxic to the host and can exert multiple hormonal
regulatory roles (44). 7a-HSDH and 7b-HSDH are two key
enzymes that drive the efficient biosynthesis of secondary
BAs such as TUDCA from TCDCA (28). Thus, the change
in microbiome composition affects the enzymatic activity
of these pathways and alters the BA pool.
Of interest is the observation that bear bile has long
been used in Chinese traditional medicine for the treat-
ment of liver, gallbladder, heart, and eye problems. Bear
bile is highly enriched in TUDCA (45). Recently, the bear
gut microbiome was used to isolate new, undiscovered
7b-HSDH enzymes for more efficient production of TUDCA
(28). Little is known regarding the protective effects of
TUDCA in the diabetic retina (46–52). However, this
hydrophilic BA can cross the blood-brain barrier and likely
can cross the blood-retinal barrier. In support of the ability
of circulating TUDCA to reach the retina and act on retinal
cells are the observations that TUDCA can inhibit photo-
receptor apoptosis (47,48,51), improve retinal pigment
epithelial function (49), inhibit proliferation of human
retinal endothelial cells (53), promote the recruitment of
endothelial progenitor cells (54), and protect against DR
(53). At the molecular level, TUDCA has been shown to
inhibit apoptosis through reduction of endoplasmic reticu-
lum stress (55) and modulation of the unfolded protein
response (56). TUDCA also inhibits mitochondrial mem-
brane depolarization (57). Receptor activation of TGR5 by
TUDCA may also decrease the production of proinflamma-
tory cytokines and induce anti-inflammatory responses
(58). Although TGR5 protein expression did not change with
IF treatment, our studies would support that TGR5 activa-
tion is central to the retinal protection observed, possibly
through eliciting anti-inflammatory effects, as INT-767 ef-
fectively prevented DR and reduced infiltration of inflam-
matory cells in the retina of STZ-treated DBA/2J mice
fed a WD that included vehicle (STZ/WD). Although INT-
767 is known as a dual agonist of TGR5 and FXR, the absence
of FXR in the retina (59) allowed us to use this highly potent
agent as a selective TGR5 agonist in the retina. However,
additional studies will be required to establish a direct link
between TGR5 activation and IF.
Our study has certain limitations that must be acknowl-
edged. First, fecal rather than mucosal bacterial samples
were used. As such, our analysis may not be representa-
tive of the entire microbiome. However, fecal sampling
is typically used in human studies. Second, we used plasma
samples rather than cecum samples for the analysis of
metabolites. Our intention was to identify microbial
metabolites that could be found in peripheral circulation,
specifically those that could target the retina. Third, we
used the db/dbmodel as a model of type 2 diabetes to study
the IF effects on microbiota. The STZ/WD model of di-
abetes was used to establish the link between TGR5
activation and prevention of DR. The STZ/WD represents
an accelerated model of DR that histologically replicates
DR seen in other diabetes models (30) and also has the
natural history and metabolic characteristics of human
metabolic syndrome and type 2 diabetes (31,32). Finally,
although we show an association between increases in
TUDCA and prevention of retinopathy, additional studies
using antibiotics or fecal transfers will be required to
demonstrate this conclusively.
In sum, our study shows a novel relationship between
changes in the microbiota, IF, and increases in TUDCA. IF
likely provides a way to change BA metabolism in favor of
increasing the endogenous generation of TUDCA (Fig. 8).
This work highlights several findings with potential clinical
significance. Diet interventions, such as IF, in diabetes
may result in a unique and highly beneficial microbiome
response. IF represents a physiological way to enhance
production of the neuroprotective TUDCA. Finally, we
Figure 8—A model for IF-induced changes in the microbiome and
their potential impact on development of DR. In diabetic mice, IF
resulted in significant expansion of bacteria of the Firmicutes phylum
that metabolize primary BAs to secondary BAs, such as TUDCA.
TUDCA then enters the circulation and crosses the blood-retina
barrier, targets its receptor, TGR5, in the ganglion cell layer and
protects against retinal neurodegeneration and inflammation.
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identify a role for TGR5 and BA signaling in the retina
that, to our knowledge, was not previously known and
may represent a new therapeutic target for DR.
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